| Document |
Document Title |
|
WO/2023/244631A1 |
A liquid laundry detergent is provided, comprising: liquid carrier; cleaning surfactant; and cleaning booster of formula (I) wherein E1 and E2 are independently selected from a divalent linking group having 1 to 4 carbon atoms; and where...
|
|
WO/2023/237729A1 |
A process for making a substantially nitrosamine-free, substantially peroxide-free, substantially colorless amine oxide solution comprises reacting a tertiary amine capable of forming an amine oxide with a less than stoichiometric amount...
|
|
WO/2023/236809A1 |
The present invention belongs to the technical field of anti-inflammatory drugs. Disclosed are a 2,6-dibenzylidene cyclohexanone oxime compound, a method for preparing same, and use thereof. According to the present invention, a structur...
|
|
WO/2023/235976A1 |
A polycation carrier particle obtained by the polymerization of a multiacrylate monomer with one or more hydrophilic monomers to form crosslinks. The polycation carrier particle has a net positive electric charge. The multiacrylate monom...
|
|
WO/2023/236976A1 |
A lipid compound and a preparation method therefor, and a use thereof. The lipid compound is safe, efficient and ionizable, and the structure of the lipid compound is divided into a hydrophilic amino group, a linking group, and a hydroph...
|
|
WO/2023/238718A1 |
Provided are: a difluorobutene acid amide compound having an excellent controlling effect against harmful weeds; and an herbicidal composition thereof. The herbicidal composition contains a difluorobutene acid amide compound represented ...
|
|
WO/2023/233397A1 |
Methods of treating pancreatic cancer or metastasis thereof by administering eravacycline or a derivative thereof are provided. Pharmaceutical compositions including eravacycline or a derivative thereof for use in treating pancreatic can...
|
|
WO/2023/229295A1 |
The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclo...
|
|
WO/2023/226241A1 |
Disclosed in the present invention are a phenylacetamide compound, and a preparation method therefor and the use thereof. The compound has a general structural formula of (aa), wherein R1 and R2 are respectively any one of -H, -OCH3, -NO...
|
|
WO/2023/222870A1 |
The present invention generally relates to the field of ionizable (also termed cationic) lipids,and in particular provides a novel type of such lipids as represented by any of the formulae disclosed herein. The present invention further ...
|
|
WO/2023/223055A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds of the present invention are papain-like protease (PLpro) inhibitors.
|
|
WO/2023/217119A1 |
Disclosed herein is a diclofenac prodrug represented by formula (I), wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed is a method for alleviating arthritis, which inclu...
|
|
WO/2023/219521A1 |
The invention relates to novel 2-(diethylamino)-4,6-diphenylbenzene-1,3-carbonitrile derivatives of general formula (1) in which R1 stands for: one of the following groups, where the dashed line indicates a bond that is, the compounds se...
|
|
WO/2023/214431A1 |
The present invention relates to a pharmaceutical composition compositions, that comprise amorphous form of pitolisant or pharmaceutically acceptable salts thereof, which is efficacious, chemically stable and physiologically balanced for...
|
|
WO/2023/202568A1 |
Disclosed in the present invention are a quaternary ammonium salt compound, and a preparation method therefor and an application thereof. The general formula of the quaternary ammonium salt compound in the present invention is as follows...
|
|
WO/2023/202477A1 |
Disclosed are a dihydromyricetin tetrahydropyrrole complex and a preparation method therefor, and an application. The molecular formula of the dihydromyricetin tetrahydropyrrole complex is as shown in formula (I). The preparation method ...
|
|
WO/2023/201067A2 |
Embodiments of the present disclosure relate to a chemical entity formed by reaction of components B and C, wherein component C is a moiety comprising one or more amine groups, and component B is a compound of Formula (I): wherein, A is ...
|
|
WO/2023/198857A1 |
The present invention provides, in part, second generation "good" buffer-based cationic lipids of Formula (I), and sub-formulas thereof: Formula (I), (I), or a pharmaceutically acceptable salt thereof. The compounds provided herein can b...
|
|
WO/2023/201301A2 |
The present disclosure relates, in part, to biodegradable lipid nanoparticles (LNPs) comprising biodegradable lipidoid compounds and compositions thereof. In certain embodiments, the LNPs selectively target a cell of interest (e.g., an i...
|
|
WO/2023/199238A1 |
The present invention relates to novel compounds of the general formula (I) having the potential to treat cytokine related disorders, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical co...
|
|
WO/2023/194601A1 |
The present invention applies to the therapeutic field of cancer. In particular, the invention relates to a compound derived from an aliphatic diamine comprising at least one pyridine or pyrimidine unit, for use as an anticancer agent, t...
|
|
WO/2023/192145A1 |
Methods of synthesizing (R)-N-(4-(4-(3-chloro-5-ethyl-2- methoxyphenyl) piperazin-l-yl)-3-hydroxybutyl)-l H-indole-2- carboxamide (compound 8) are described as well as intermediate compounds of formulae 5-7, 9 and 14 used in said methods.
|
|
WO/2023/191533A1 |
The present invention relates to a thiobenzimidazole derivative preparation method, a novel intermediate therefor, and the like. The present invention uses an intermediate containing O-ethyl carbonodithioate or an intermediate containing...
|
|
WO/2023/190166A1 |
The present invention provides: a cationic lipid that can be used as a nucleic acid delivery carrier having excellent intercellular behavior; a lipid membrane structure including the same; a nucleic acid introduction agent and a pharmace...
|
|
WO/2023/190472A1 |
[Problem] To provide at least one selected from among a novel cyclohexylenediaminium salt, a production method therefor, a use thereof, and an MSE type zeolite obtained using same. [Solution] An MSE type zeolite having the X-ray powder d...
|
|
WO/2023/186149A1 |
The present invention relates to the technical field of biomedicines, and particularly disclosed are a lipid compound, a composition containing the same, and use thereof. The lipid compound has a structure represented by formula (I) or f...
|
|
WO/2023/187051A1 |
A process for the production of a surfactant is provided, as well as a surfactant composition. Moreover, specific surfactants and compositions thereof are provided, as well as their use in a wide variety of applications such as all purpo...
|
|
WO/2023/187762A1 |
The present invention relates to co-crystals of Vortioxetine hydrobromide, process for its preparation and pharmaceutical composition comprising the same.
|
|
WO/2023/192664A2 |
Disclosed herein are compounds for treating a condition modulated by calcium channel ion activity and pharmaceutical compositions comprising the compounds, wherein the compounds comprise a diazaspiroheptane core and left- and right-hand ...
|
|
WO/2023/182756A1 |
The present invention relates to a novel ionizable lipid and a lipid nanoparticle composition using same. It has been identified that the lipid nanoparticle caused by the novel ionizable lipid exhibits an excellent rate of gene encapsula...
|
|
WO/2023/179110A1 |
Disclosed is a method for synthesizing polyethylene polyamine under catalysis, wherein monoethanolamine and ethylenediamine are used as main raw materials, and are subjected to hydroamination under the action of a catalyst so as to obtai...
|
|
WO/2023/181676A1 |
The present invention provides a polyamine which includes a ring-containing polyamine that has a piperazine ring, and which is configured such that at least one of two nitrogen atoms in the piperazine ring is bonded with a chain substitu...
|
|
WO/2023/183886A2 |
Disclosed herein are DMZ-derived compositions for and methods of modulating the expression and/or function of disease associated and/or diseasing causing secondary RNA structures and tertiary RNA structures.
|
|
WO/2023/174056A1 |
The present invention discloses a multifunctional macromolecular photoinitiator containing α-aminoketone, and a preparation method therefor and the use thereof, which belong to the technical field of new material organic chemicals. The ...
|
|
WO/2023/177877A1 |
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist co...
|
|
WO/2023/168484A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)
|
|
WO/2023/172415A1 |
Described herein are compounds useful as sweet flavor modifiers. Ingestible compositions that include one or more of these compounds in combination with a natural or artificial sweetener are also described. (I)
|
|
WO/2023/171801A1 |
Provided are crystals of a vitamin D derivative represented by formula (1) or crystals of a solvate of a vitamin D derivative represented by formula (1). Such crystals are useful as a pharmaceutical for promoting induction of differentia...
|
|
WO/2023/168022A1 |
The invention relates to a co-crystal or salt comprising psilocybin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoraliz...
|
|
WO/2023/168023A1 |
The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralizat...
|
|
WO/2023/166103A1 |
The present invention relates to compounds of formula (I), wherein R1 to R8, Y, A, Q, X and M are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the ...
|
|
WO/2023/160035A1 |
A β-elemene vinylation coupled derivative, and a preparation method therefor and the use thereof in the preparation of an antitumor drug. Provided are a β-elemene vinylation coupled derivative having a structure as represented by formu...
|
|
WO/2023/160039A1 |
Disclosed in the present invention are a β-elemene derivative with an HDACi pharmacophore, and a preparation method therefor and the use thereof. Provided in the present invention are a β-elemene derivative with an HDACi pharmacophore ...
|
|
WO/2023/161505A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity, pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditi...
|
|
WO/2023/163945A1 |
The instant disclosure provides methods and pharmaceutical compositions for the treatment of congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), as well as a method of reducing androgen levels in a human in need th...
|
|
WO/2023/160583A1 |
Disclosed are 1-hydroxy-2-naphthoate or bis-hydroxynaphthenate of cariprazine, a new solid form thereof, a pharmaceutical composition thereof, and a preparation method therefor and the use thereof. The cariprazine salt and the solid form...
|
|
WO/2023/163541A1 |
The present invention relates to novel ionized lipids and lipid nanoparticle comprising the ionized lipids. A therapeutic agent using the lipid nanoparticles comprising novel-type ionized lipids according to the present invention can min...
|
|
WO/2023/153494A1 |
The present invention addresses the problem of providing a new catalyst for selectively generating formamides from urea-based compounds and urethane-based compounds. The present invention pertains to: a complex having a partial structure...
|
|
WO/2023/153504A1 |
A nucleic acid delivery material containing a perylene-diimide-ring-free polycyclic aromatic compound having one or more primary, secondary, or tertiary amino groups or nitrogen-cation-containing groups has exceptional efficiency in nucl...
|
|
WO/2023/147658A1 |
The present application relates to the use of 3,3'-(1,3-phenylenebis(oxy))bis(1-(piperidin-1- yl)propan-2-ol (VE607) or a pharmaceutically acceptable salt thereof for the inhibition of SARS-CoV- 2 and/or management of COVID-19.
|
